Visceral Fat: Which Works Better — Diet, Mounjaro, or Tesamorelin?

Visceral fat isn't the soft layer under your skin that bothers you in the mirror. It's fat that wraps around your internal organs and quietly releases inflammatory molecules that destroy metabolic health [4]. And it's the one you can't see.

If there's one type of fat that's truly dangerous, it's this one. But what if it could be removed selectively? Sounds like the myth of spot reduction? In the case of Tesamorelin — it's confirmed by double-blind randomized studies [4].

Three approaches to visceral fat: what to choose?

When it comes to dangerous abdominal fat, there are three fundamentally different strategies. First — classic caloric deficit with exercise. Second — GLP-1 agonists like Mounjaro or Ozempic. Third — the peptide Tesamorelin, which FDA approved back in 2010 under the brand Egrifta [3].

Each of these approaches works through different mechanisms. And each gives different results. Caloric deficit reduces total body mass, and visceral fat goes as part of this process. GLP-1 drugs suppress appetite and slow gastric emptying, leading to substantial weight loss and VAT (visceral adipose tissue) reduction as a side effect [30]. Tesamorelin works fundamentally differently — it stimulates your own pituitary to produce growth hormone and is selectively targeted at visceral fat [1].

Caloric deficit and exercise: how much VAT can be lost?

The classic approach — restrict calories and add physical activity. Research shows that even modest weight loss of 5-10% of total body mass leads to significant visceral fat reduction, sometimes proportionally greater than subcutaneous [22].

In a randomized study of 95 overweight women who completed a 6-month program, average weight loss was 12.1 kg. All groups showed similar visceral fat reduction — approximately 25% [38]. This is a substantial result. But there's a nuance: diet-only groups lost relatively more muscle mass than those who added exercise [38].

Which exercises are most effective for VAT? A systematic review of clinical studies established that at least 10 MET-hours per week of aerobic exercise are needed — brisk walking, light jogging, or stationary cycling — to reduce visceral fat [43]. And there's a dose-dependent response: more intensity — more results.

HIIT (high-intensity interval training) and aerobic exercises show the best results for VAT reduction in overweight people [41]. Resistance training also helps by increasing muscle mass and resting metabolic rate [42].

However, there's a problem. Caloric deficit is not selective. You lose fat from everywhere, not just from the dangerous zone around organs. And if the deficit is too aggressive, you risk losing muscle and triggering the yo-yo effect [40]. NHS and NICE recommendation — moderate deficit of about 500 calories per day for approximately 0.5 kg weight loss per week [22].

GLP-1 agonists: VAT reduction as a side effect of weight loss

Mounjaro and Ozempic are weight loss drugs originally developed for type 2 diabetes control. They work through GLP-1 (glucagon-like peptide-1) receptors, suppressing appetite and slowing digestion [8].

Mounjaro (tirzepatide) is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) agonist. In the SURMOUNT-1 study, participants on the maximum 15 mg dose lost an average of 22.5% weight over 72 weeks [19]. Ozempic (semaglutide) in the STEP study showed 15-17% weight loss on 2.4 mg dose over 68 weeks [19].

Regarding visceral fat: GLP-1 agonists produce disproportionate VAT reduction relative to total weight loss [17]. This means visceral fat goes faster than could be predicted from scale numbers alone. The SURPASS-3 MRI study showed significant reduction in abdominal fat and liver fat on tirzepatide [34].

However, there's an important caveat. GLP-1 drugs are not selective for visceral fat. They reduce total body mass, and VAT goes as part of this process [30]. If your goal is to lose weight and improve overall metabolic health, it's an excellent tool. If you need to specifically target visceral fat without losing subcutaneous fat or muscle, the GLP-1 mechanism wasn't created for this.

GLP-1 side effects: what to know

Both drugs have similar side effect profiles — predominantly gastrointestinal: nausea, vomiting, diarrhea, constipation [8]. FAERS database analysis showed semaglutide has the highest risk of GI effects among GLP-1 agonists with odds ratio 7.41 for nausea [5].

Regarding pancreatitis: meta-analysis of randomized trials found no increased risk of acute pancreatitis compared to placebo (odds ratio 0.7, 95% CI 0.5-1.2) [13]. Under specialist supervision, these effects are manageable, and most clients tolerate them well.

Tesamorelin: selective visceral fat reduction

Now the most interesting part. Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It's not growth hormone itself, but stimulates your own pituitary to produce GH in natural pulsatile rhythm [4].

Why is this important? When you inject growth hormone directly, you disrupt natural rhythm. You get persistent, non-physiological elevation. And that's when side effects appear: joint pain, fluid retention, insulin resistance [4]. Tesamorelin preserves the body's natural feedback mechanisms.

Clinical trial results: LIPO-2009

Two large placebo-controlled randomized Phase III studies with identical enrollment criteria showed impressive results [20]. In pooled analysis, visceral fat decreased by 15.4% compared to placebo over 26 weeks [16].

Here's what makes this data special: in a double-blind placebo-controlled 26-week study, patients on tesamorelin showed about 15% visceral fat reduction, while the placebo group actually gained some VAT [4]. The graph shows clear line divergence.

Even more interesting: this reduction was specific to visceral fat, not subcutaneous [4]. Yes, this should make you stop and think.

For participants who continued therapy to 52 weeks, net VAT reduction was approximately 18%, corresponding to 3.4 cm waist circumference reduction — almost exclusively from visceral fat [16]. In another study with INSTI regimens, participants on tesamorelin showed median visceral fat reduction of 25 cm² versus 14 cm² increase in placebo group [23].

What else does Tesamorelin do?

Tesamorelin significantly reduces liver fat [12]. In the study, hepatic lipid index decreased by -2.0% in the tesamorelin group versus +0.9% in placebo, net effect -2.9% [12]. This is important because non-alcoholic fatty liver disease is closely linked to visceral obesity.

Clinical studies showed tesamorelin significantly reduces visceral adipose tissue without negatively affecting subcutaneous fat and without inducing insulin resistance [1]. Moreover, elevated GH/IGF-1 levels promote muscle mass preservation [7] — something difficult to achieve with regular caloric deficit.

Comparison of all three approaches

Here's the key difference. If your goal is significant total weight loss and overall metabolic health improvement, Mounjaro or Ozempic provide highest efficacy [19]. Tirzepatide 15 mg in SURMOUNT-1 showed 22.5% weight loss — the highest result in randomized controlled trials, approaching bariatric surgery results [17].

If your goal is to specifically target visceral fat without significant total weight loss, without GI side effects, and with muscle mass preservation, Tesamorelin is the only option with RCT-confirmed selectivity [2].

Combined approach: how to get maximum results

Importantly: these approaches are not mutually exclusive. Moderate caloric deficit with physical activity remains the foundation for any weight correction program [22]. GLP-1 agonists can significantly ease adherence to this deficit by reducing appetite [26].

Tesamorelin works through a fundamentally different mechanism — endogenous GH stimulation — and theoretically could complement GLP-1 therapy for those wanting to additionally target VAT [2]. However, clinical data on such combination is still insufficient.

What definitely works: combining any pharmacological approach with HIIT training. Studies showed visceral fat changes are inversely proportional to VO2max improvement — the more aerobic fitness improved, the more VAT was lost [38].

What to choose: practical recommendations

If you're just starting your healthy weight journey, a reasonable first step is assessing your visceral fat. DEXA scanning or MRI provide accurate data [33]. Waist circumference over 102 cm in men or 88 cm in women is a red flag [39].

For most overweight people, DOZA weight loss program with Mounjaro will be the most effective solution. You get significant weight loss, VAT reduction, improved glycemic control, and cardiovascular markers — all in one [21].

For those already close to normal weight but with localized visceral fat accumulation, Tesamorelin offers a unique selective approach. It's the only peptide in the GHRH-analog class with FDA approval for visceral fat reduction and the best clinical evidence profile [2].

And caloric deficit + exercise? This works for everyone — as foundation, as supplement, as result maintenance. Don't ignore the basics.

Where to order DOZA products

DOZA supplies all products mentioned in the article with official cold chain and 24/7 specialist support. Choose what you need:

• Buy Mounjaro in Ukraine — DOZA catalog with all 6 doses (2.5, 5, 7.5, 10, 12.5, 15 mg) and official thermal delivery within 24 hours. Current Mounjaro prices 2026 — from ₴1,000 for test dose.
• Buy Ozempic in Ukraine — original semaglutide from Novo Nordisk with thermal delivery. Current Ozempic prices 2026 — from ₴1,600 for starter dose.

Where to buy

DOZA supplies the products mentioned in this article with an official cold chain and 24/7 specialist support:

• Buy Tesamorelin in Ukraine — FDA-approved GHRH analog for visceral fat reduction.

FAQ